Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 1, 2000, Pages 179-186

  Shetty, Suraj S ^a   Delgrande, Dominick ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; EPROSARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

ANIMAL EXPERIMENT; ARTICLE; DRUG INHIBITION; DRUG POTENCY; MALE; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RECEPTOR BINDING; REGRESSION ANALYSIS; SYMPATHETIC TONE;

ACRYLATES; ANGIOTENSIN II; ANIMALS; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; IMIDAZOLES; LOSARTAN; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ANGIOTENSIN; SYMPATHETIC NERVOUS SYSTEM; TETRAZOLES; THIOPHENES; VALINE;

EID: 0033919444     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abadie C, Foucart S, Page P and Nadeau R (1996) Modulation of noradrenaline release from isolated human atrial appendages. J Auton Nerv Syst 61:269-276.
2. Adams MA, Bobik A and Korner PI (1989) Differential development of vascular and cardiac hypertrophy in genetic hypertension: Relation to sympathetic function. Hypertension 14:191-202.
3. 3H-efflux and atrial rate in guinea-pig atrium. Br J Pharmacol 81:201-214.
4. Benjamin N, Collier JG and Webb DJ (1988) Angiotensin II augments sympathetically induced venoconstriction in man. Clin Sci 75:337-340.
5. Brasch H, Sieroslawski L and Dominiak P (1993) Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 22:699-704.
6. Bumpus FM, Catt KJ, Chiu AT, DeGasparo M, Goodfriend T, Husain A, Peach MJ, Taylor DG Jr and Timmermans PB (1991) Nomenclature for angiotensin receptors: A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 17:720-721.
7. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL and Pieter BMWM (1989) Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 166:196-203.
8. Chulak C, Couture R and Foucart S (1995) Modulatory effect of bradykinin on the release of noradrenaline from rat isolated atria. Br J Pharmacol 115:330-334.
9. Cox SL, Ben A, Story DF and Ziogas J (1995) Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol 114:1057-1063.
10. Cox SL, Story DF and Ziogas J (1996) Multiple prejunctional actions of angiotensin II on noradrenergic transmission in the caudal artery of the rat. Br J Pharmacol 119:976-984.
11. Criscione L, Bradley WA, Buhlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P and de Gasparo M (1995) Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13:230-250.
12. 3H]norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats. Am J Hypertens 9:61-69.
13. Francis GS (1989) The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J 118:642-648.
14. 3H-noradrenaline uptake and tissue concentrations of desipramine, protriptyline and doxepin in rat isolated atria. Arch Int Pharmacodyn Ther 224:55-65.
15. Fuder H and Muscholl E (1995) Heteroreceptor-mediated modulation of noradrenaline and acetylcholine release from peripheral nerves. Rev Physiol Biochem Pharmacol 126:265-412.
16. Grieve AP (1996) On likelihood and Bayesian methods for interval estimation of the LD50, in Statistics in Toxicology (Morgan BJT ed) pp 87-100, Oxford University Press, Oxford.
17. Guimaraes S, Paiva MQ and Moura D (1998) Different receptors for angiotensin II at pre- and postjunctional level of the canine mesenteric and pulmonary arteries. Br J Pharmacol 124:1207-1212.
18. Judy WV, Watanabe AM, Henry DP, Besch HR Jr, Murphy WR and Hockel GM (1976) Sympathetic nerve activity: Role in regulation of blood pressure in the spontaneously hypertensive rat. Circ Res 38:21-29.
19. Leier CV, Binkley PF and Cody RJ (1990) a-Adrenergic component of the sympathetic nervous system in congestive heart failure. Circulation 82 (Suppl I):I-68-I-76.
20. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI and Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58:641-649.
21. Marino MR, Langenbacher KM, Raymond RH, Ford NF and Lasseter KC (1998) Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 38:347-356.
22. Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N and Jorkasky DK (1998) Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 38:129-137.
23. Mendelsohn FA (1985) Localization and properties of angiotensin receptors. J Hypertens 3:307-316.
24. Meredith IT, Broughton A, Jennings GL and Esler MD (1991) Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325:618-624.
25. Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M and Lloyd P (1997) The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin Pharmacol Ther 61:35-44.
26. Munch G, Kurz T, Urlbauer T, Seyfarth M and Richardt G (1996) Differential presynaptic modulation of noradrenaline release in human atrial tissue in normoxia and anoxia. Br J Pharmacol 118:1855-1861.
27. Nicholas TE (1970) Potentiation of the effects of noradrenaline and of sympathetic stimulation of the perfused rat caudal artery by angiotensin. J Pharm Pharmacol 22:37-41.
28. Ohlstein EH, Brooks DP, Feuerstein GZ and Ruffolo RR Jr (1997) Inhibition of sympathetic outflow by angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 55:244-251.
29. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T and Nakashima M (1993) Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 35:290-297.
30. Rand MJ, Majewski H and Story DF (1990) Modulation of neuroeffector transmission, in Cardiovascular Pharmacology, 3rd ed. (Antonaccio M ed) pp 229-292, Raven Press, New York.
31. Rector TS, Olivari MT, Levine TB, Francis GS and Cohn JN (1987) Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 114:148-152.
32. Rump LC, Oberhauser V, Schwertfeger E and Schollmeyer P (1998) Experimental evidence to support ELITE. Lancet 351:644-645.
33. 2-Adrenergic receptor and angiotensin II receptor modulation of sympathetic neurotransmission in human atria. Circ Res 74:434-440.
34. Seidelin PH, Collier JG, Struthers AD and Webb DJ (1991) Angiotensin II augments sympathetically mediated arteriolar constriction in man. Clin Sci 81:261-266.
35. Tofovic SP, Pong AS and Jackson EK (1991) Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension 18:774-782.
36. Wenting GJ, Man in't veld AJ, Woittiez AJ, Boomsma F, Laird Meeter K, Simoons ML, Hugenholtz PG and Schalekamp MA (1983) Effects of captopril in acute and chronic heart failure: Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J 49:65-76.
37. Westfall TC (1977) Local regulation of adrenergic neurotransmission. Physiol Rev 57:659-728.
38. Whitebread S, Mele M, Kamber B and de-Gasparo M (1989) Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 163:284-291.
39. Wong PC, Bernard R and Timmermans PBMWM (1992) Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension 19:663-667.
40. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM (1990) Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 255:211-217.